Physician profile
John H Smith
NPI 1447230750
$3,469.97
in general payments reported to CMS, 2019-2025
33 companies · $1,197 in 2025
The $1,197 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $674 · 2020: $94.02 · 2021: $14.63 · 2022: $148 · 2023: $594 · 2024: $748 · 2025: $1,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,538.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $923.60 | 2019-2025 | Viberzi, Linzess, Rinvoq |
| Gilead Sciences, INC. | $604.56 | 2019-2025 | |
| Janssen Biotech, INC. | $214.97 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $200.10 | 2023-2025 | Entyvio, Gattex |
| Ardelyx, INC. | $161.50 | 2023-2025 | Ibsrela |
| Boston Scientific Corporation | $148.44 | 2019 | |
| Novo Nordisk INC | $127.85 | 2025 | Wegovy |
| Janssen Scientific Affairs, LLC | $124.20 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $96.63 | 2023-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.87 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Madrigal Pharmaceuticals | $74.34 | 2025 | Rezdiffra |
| Fujifilm Healthcare Americas Corporation | $72.61 | 2024-2025 | Utaswako Afp-L3 |
| Celgene Corporation | $67.00 | 2022-2024 | Zeposia |
| Braintree Laboratories, INC. | $60.65 | 2019-2023 | Suflave |
| Pfizer INC. | $54.97 | 2023-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $51.63 | 2025 | Gi Genius |
| Genzyme Corporation | $46.70 | 2023 | |
| Orphalan INC | $45.81 | 2025 | Cuvrior |
| Intercept Pharmaceuticals, INC. | $44.07 | 2019-2023 | Ocaliva |
| Qol Medical, LLC | $38.46 | 2024 | Sucraid |
| Enterra Medical, INC. | $37.23 | 2025 | |
| Merck Sharp & Dohme LLC | $35.41 | 2020-2023 | Dificid |
| Lilly USA, LLC | $32.10 | 2025 | Omvoh |
| Genentech USA, INC. | $28.08 | 2022 | |
| Alnylam Pharmaceuticals INC. | $26.86 | 2024 | Givlaari |
| Ironwood Pharmaceuticals, INC | $23.18 | 2024 | |
| W. L. Gore & Associates, INC. | $19.60 | 2023 | Gore Cardioform Septal Occluder |
| Daiichi Sankyo INC. | $17.76 | 2019 | |
| Intra-Sana Laboratories | $15.79 | 2023 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.